Granneman G R, Sennello L T, Steinberg F J, Sonders R C
Antimicrob Agents Chemother. 1982 Jan;21(1):141-5. doi: 10.1128/AAC.21.1.141.
This study was concerned with the single-dose, pharmacokinetics of cefmenoxime after intramuscular (i.m.) injections of 250, 500 and 1,000 mg; 1-h intravenous (i.v.) infusions of 500, 1,000, and 2,000 mg; and 5-min i.v. injections of 500, 1,000, and 2,000 mg of cefmenoxime. A total of 15 subjects were used, each receiving all three doses for one route of administration. Mean calculated peak plasma levels after the 250-, 500-, and 1,000-mg i.m. doses were 9.07, 14.68, and 26.73 micrograms/ml, respectively, occurring about 40 min after dosing. The biphasic decline in plasma levels after i.v administration was usually not apparent after i.m. dosing, because absorption of the drug from the injection depot was slower than distribution of the drug. Mean calculated peak levels from the 500-, 1,000-, and 2,000-mg i.v. doses were 22.8, 41.6, and 94.5 micrograms/ml, respectively, after the 1-h infusions and 64.1, 100.9, and 198.2 micrograms/ml, respectively after the 5-min injections. Small but statistically significant trends of decreasing alpha and increasing volume of distribution (central compartment) with increasing dose size were noted; however, this distribution phenomenon was self-compensating, resulting in no overall effect on plasma clearance. For practical purposes, the pharmacokinetics were linear. The mean 0- to 24-h urinary recoveries of cefmenoxime after the i.m. injections, i.v. infusions, and i.v. injections were 72.1, 67.5, and 74.5% respectively. Overall, the pharmacokinetics of cefmenoxime were best described by a two-compartment open model with a beta-phase half life of 0.91 h. Plasma clearance of the drug was dosage level and route independent, averaging 254 ml/min; thus, there was an excellent linear relationship between the area under the plasma level curve and the dose. The results of this study indicated that most of the drug is removed by renal mechanisms, with tubular secretion predominating.
本研究关注头孢甲肟在肌内注射250、500和1000mg;静脉滴注500、1000和2000mg持续1小时;以及静脉注射500、1000和2000mg持续5分钟后的单剂量药代动力学。总共使用了15名受试者,每人接受三种剂量中的所有剂量,采用一种给药途径。250mg、500mg和1000mg肌内注射剂量后的平均计算峰血浆水平分别为9.07、14.68和26.73μg/ml,给药后约40分钟出现。静脉给药后血浆水平的双相下降在肌内给药后通常不明显,因为药物从注射部位的吸收比药物分布慢。500mg、1000mg和2000mg静脉滴注剂量在1小时输注后的平均计算峰水平分别为22.8、41.6和94.5μg/ml,5分钟注射后的平均计算峰水平分别为64.1、100.9和198.2μg/ml。随着剂量增加,观察到α减小和分布容积(中央室)增加的微小但具有统计学意义的趋势;然而,这种分布现象是自我补偿的,对血浆清除率没有总体影响。实际上,药代动力学是线性的。肌内注射、静脉滴注和静脉注射后头孢甲肟0至24小时的平均尿回收率分别为72.1%、67.5%和74.5%。总体而言,头孢甲肟的药代动力学最好用二室开放模型描述,β相半衰期为0.91小时。药物的血浆清除率与剂量水平和给药途径无关,平均为254ml/min;因此,血浆水平曲线下面积与剂量之间存在良好的线性关系。本研究结果表明,大部分药物通过肾脏机制清除,以肾小管分泌为主。